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Intervertebral disc degeneration is strongly associated with chronic low back pain, a leading cause
of disability worldwide. Current back pain treatment approaches (both surgical and conservative)
are limited to addressing symptoms, not necessarily the root cause. Not surprisingly therefore,
long-term efficacy of most approaches is poor. Cell-based disc regeneration strategies have
shown promise in preclinical studies, and represent a relatively low-risk, low-cost, and durable
therapeutic approach suitable for a potentially large patient population, thus making them attrac-
tive from both clinical and commercial standpoints. Despite such promise, no such therapies have
been broadly adopted clinically. In this perspective we highlight primary obstacles and provide
recommendations to help accelerate successful clinical translation of cell-based disc regeneration
therapies. The key areas addressed include: (a) Optimizing cell sources and delivery techniques;
(b) Minimizing potential risks to patients; (c) Selecting physiologically and clinically relevant effi-
cacy metrics; (d) Maximizing commercial potential; and (e) Recognizing the importance of multidis-
ciplinary collaborations and engaging with clinicians from inception through to clinical trials.
KEYWORDS
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1 | INTRODUCTION
Lower back pain is a leading cause of disability worldwide and the
third most expensive health condition in the United States, with
estimated health care spending in excess of $80 billion annually.1,2 It
is a significant epidemiological and socioeconomic problem affecting
quality of life, and is the most common, non-cancer reason for opioid
prescription in the United States.3 Intervertebral disc degeneration is
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a progressive, cell-mediated cascade of molecular, structural and bio-
mechanical changes, which is strongly implicated as a cause of “disco-
genic” back pain.4 The incidence of disc degeneration is linked to
aging, trauma, genetics, lifestyle and the presence of co-
morbidities.5–9 The intervertebral discs are the pliant, fibrocartilagi-
nous joints required for transferring compressive loads and supporting
complex mobility of the spine.10 Each disc is comprised of a central,
proteoglycan-rich, gelatinous nucleus pulposus (NP), a peripheral,
fibrocartilaginous annulus fibrosus (AF), and superiorly and inferior,
hyaline cartilage end plates that interface with the vertebral bodies.10
The earliest degenerative changes typically manifest in the NP, where
reductions in proteoglycan content and hydration compromise biome-
chanical function, leading to progressive degeneration of the entire
intervertebral joint.11,12 Self-repair and regeneration of the NP is lim-
ited by a low cell density and a limited nutrient supply.13,14 Conven-
tional treatments for disc degeneration are focused solely on
alleviation of symptoms and often have limited long-term
efficacy.15–17 This is exacerbated by the lack of an accepted clinical
standard for discogenic pain, where clinicians are often unable to
identify a specific nociceptive cause.18,19 Because of this, the rationale
for choosing surgery for these patients is controversial. Spinal fusion
does not restore natural biomechanical function and has been shown
to induce adjacent segment pathology (ASP) caused by increased
mechanical stress in adjacent segments.20 More specifically, in a study
comparing 725 lumbar fusion cases to 725 randomly selected controls
with chronic low back pain diagnoses, focusing on the outcome return
to work (RTW) revealed only 26% of patients had RTW 2 years after
fusion surgery, while 67% of nonsurgical controls had RTW within
2 years from the date of injury.21 In addition, of the patients receiving
spinal fusion, 36% had complications and the reoperation rate was
27%, with 66% of the reoperations occurring within 2 years of the
index surgery. Of the 36% of complications, failed and/or implant mal-
position represented 4.7% of cases, while late spinal complications
such as disc space infection, pseudarthrosis, postlaminectomy syn-
drome, adjacent disc degeneration, stenosis, spondylolisthesis, and
adjacent vertebral fracture represented 25.2% of cases, with the bal-
ance relating to early major systemic, neurologic and wound
complications.
There is therefore a tremendous unmet need for new treatment
options for patients with disc degeneration and associated lower back
pain. To address this need, there has been significant recent interest
in developing injectable cell-based therapies for the treatment of disc
degeneration with the specific aim to stimulate tissue repair.22 Such
therapies represent a potentially low risk and low cost long term solu-
tion for a very large patient population, making them attractive from
both clinical and commercial standpoints.
The pathway to bringing new cell therapies to patients involves
extensive in vitro testing, pre-clinical validation in small and large
animal models, and human clinical trials to demonstrate safety,
efficacy, and commercial viability. Successful translation involves
multidisciplinary engagement and interactions between clinicians,
scientists, engineers and industry. Clinicians are particularly impor-
tant as they can provide access to primary human cells, advise on
patient selection criteria and outcome metrics, assist with the design
and conduct of clinical trials, support risk/value discussions with
regulatory and reimbursement agencies, and advocate the treatment
to patients and health systems.
Even after demonstrating success in animal studies, cell-based
therapies are at risk of stalling in the “valley of death”, which com-
prises multiple significant barriers that include scale-up, manufactur-
ing, regulatory, business and market obstacles. To effectively move
cell therapies out of the lab and into the clinic, the following must be
considered and addressed: (a) Optimizing cell sources and delivery
techniques; (b) Minimizing potential risks to patients; (c) Selecting
physiologically and clinically relevant efficacy metrics; (d) Working
with industry and maximizing commercial potential; and
(e) Recognizing the importance of forming multidisciplinary collabora-
tions and engaging with clinicians from inception through to clinical
trials. The focus of this article is to highlight and comprehensively
review each of these critical areas, and in doing so provide a set of
recommendations for successfully advancing cell-based disc therapies
from the lab to the clinic for first-in-human studies.
2 | CURRENT COMMERCIAL APPROACHES
FOR CELL-BASED DISC REPAIR AND
REGENERATION
A small number of companies have successfully entered the clinic to
evaluate the efficacy of cell-based disc regeneration treatments in
humans. These treatments have employed a variety of cell types
including those obtained from both homologous (from the disc) and
non-homologous (eg, from knee cartilage, adipose tissue) sources, and
have utilized both autologous and allogeneic approaches. Autologous
Disc Cell Transplantation (ADCT) by Co.Don AG (Berlin, Germany) has
been in clinical use for the treatment of degenerate discs for a number
of years,23 with recent investigations demonstrating that re-
implantation of culture-expanded NP cells can retard degenerative
changes in patients with herniated discs24; however, there are limita-
tions associated with ADCT delivery and efficacy, including cell leak-
age following injection into the disc,25 diminished tissue forming
capacity of culture expanded NP cells derived from degenerated tis-
sue26 and the paucity of NP cells that can be isolated. The challenge
of cell leakage is not unique to ADCT per se, and is a function of the
delivery and surgical techniques employed. Any cell therapy relying on
intradiscal needle delivery in a saline solution will likely suffer similar
failings unless it is combined with some form of biomaterial (eg,
hydrogel, microcarriers, microcapsules), which can enhance cellular
retention in the disc space.
Two companies have disclosed results from initial clinical trials
and have subsequently progressed to performing additional clinical tri-
als. ISTO Biologics (St. Louis, Missouri) reported promising results
from a Phase I study evaluating allogeneic juvenile chondrocytes
mixed with a fibrin carrier,27 known as NuQu; however the Phase II
study was recently terminated for undisclosed reasons (clinicaltrials.
gov study identifier NCT01771471). Mesoblast Ltd. (Melbourne,
Australia) also showed promising results using immunoselected
adipose-derived mesenchymal stem cells (MSCs) injected into the
discs of patients, including finding that the treatment resulted in pain
relief and improved water content in treated discs compared to
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controls.28,29 When injected into degenerate ovine discs, these cells
were shown to elicit regenerative effects.30 A larger, multi-national
Phase III study is ongoing to better assess the potential efficacy and
safety of this treatment (clinicaltrials.gov study identifier
NCT02412735). Biorestorative (Melville, New York) has evaluated
BRTX-100, an autologous stem cell therapy, in a preliminary human
clinical study and has investigational new drug (IND) approval to start
a trial in the United States (no clinicaltrials.gov information available).
A number of other companies are currently executing first-in-
human clinical trials. Utilizing cells modified from adult disc tissue,
DiscGenics Inc. (Salt Lake City, Utah) is conducting a clinical trial to
evaluate safety and efficacy of the product candidate IDCT (injectable
discogenic cell therapy) compared to controls over 2 years
(clinicaltrials.gov study identifier NCT03347708). IDCT contains a
mixture of specialized therapeutic progenitor cells engineered from
donated adult disc tissue, or “discogenic” cells and a viscous carrier
material. Promising animal data suggests a potential therapeutic bene-
fit of IDCT, including disc height improvement and normalization of
disc architecture, and a safe profile.31 Aesculap Biologics (Breinigsville,
Pennsylvania) is currently testing NOVOCART DISC in a Phase II trial
in the European Union. This treatment is a combination of autologous
disc chondrocytes and a self-polymerizing hydrogel (clinicaltrials.gov
study identifier NCT01640457) that is already being used clinically for
articular cartilage repair in the knee. Preliminary results from the
Phase I trial of this therapy indicate the risks of adverse events occur-
ring are comparable to elective disc surgery.32
In summary, commercial efforts to date have applied an extensive
variety of cell-based approaches for treating disc degeneration. While
some of these have shown encouraging preclinical and clinical findings
with respect to both safety and efficacy, none have achieved wide-
spread clinical adoption.
3 | PATIENT SELECTION: EVEN THE BEST
THERAPY WON'T SUCCEED IF APPLIED TO
THE WRONG DISC
For effective clinical translation it will be important to stratify patient
cohorts, for example using sophisticated magnetic resonance imaging
techniques33–37 and quantification of circulating biomarkers38 to
select suitable candidates for treatment. The opportunity for cell-
based therapy may be most appropriate at the early stage of the
degenerative cascade, prior to the onset of advanced disc degenera-
tion coupled with endplate calcification and extensive annular degen-
eration.39 As a first step, patient selection for cell-based therapies
should therefore be limited to single-level, moderate severity disc
degeneration, which is reflected by Pfirrmann Grade III or IV on MRI.
Patients presenting with a Pfirrmann grade of II or V may represent
a patient population either too mild or too advanced in the disease
process to show measurable improvement.40
Currently, patient selection for intradiscal therapies includes
chronic back pain (>4 VAS) and disability (>40 ODI) that is refractory
to conservative care (longer than 6 months). Potential patients are
excluded if there is evidence of clinically-relevant vertebral/spinal
abnormalities that include spondylolisthesis, spondylolysis, scoliosis,
fracture, severe kyphosis, or disc herniation. Herniation patients may
be suitable candidates for treatment if intradiscal therapies are applied
in combination with AF repair. Within appropriate individuals, the
offending level(s) is typically identified by imaging (MRI) plus other
clinical criteria that may include invasive techniques such as provoca-
tive discography. While current imaging techniques can provide exqui-
site anatomic detail, standard MRI sequences do poorly at identifying
specific pain generators.41 Recently, a group of international experts
concluded that there is no accepted clinical standard for discogenic
pain.18,19,42,43 Equally important, treatment outcomes are currently
judged by subjective and qualitative patient reports, which can be
influenced by significant placebo effects.44 Therefore, to support clini-
cal application and evaluation of intradiscal cellular therapies, there is
a critical need for new techniques that localize pain generators and
quantify therapeutic effects on treated levels. New, advanced imaging
tools for this purpose are currently in development and have been
summarized in several recent reviews.45,46 Examples include MRI
techniques such as T1ρ and T2 relaxation times, and chemical
exchange saturation transfer (CEST), which, unlike more widely used
subjective grading disc grading schemes, are quantitative surrogates
for disc composition.
4 | OPTIMIZING CELL SOURCES
AND DELIVERY TECHNIQUES
4.1 | The challenges of the degenerate disc
microenvironment
The rationale for and benefits of delivery of cells to the NP are 2-fold:
firstly, transplanted cells may stimulate endogenous NP cells to pro-
duce neo-matrix through paracrine effects; and secondly transplanted
cells may adopt an NP cell-like phenotype and directly reconstitute
native tissue.47,48 A central challenge, however, that limits the poten-
tial of cell-based regeneration is the harsh local cellular microenviron-
ment within the degenerate disc, which is characterized by low
oxygen and nutrient supply, increased acidity, altered osmolarity, as
well as elevated levels of pro-inflammatory cytokines.49–54 Therefore,
there is a clear need to identify robust cell populations to enhance the
likelihood of survival post-injection, and characterize how such cells
will function in the typical degenerate microenvironment to determine
if they can contribute effectively to functional disc repair. The precise
cell number for intradiscal delivery needs to be carefully considered,
and to-date the exact number of cells required for functional regener-
ation is unclear. This will most likely depend on the cell-type being
employed as well as the metabolic activity and percentage survival
post intradiscal delivery. A recent review of clinical trials by Sakai and
Schol reported cell numbers ranging from 1 to 40 million cells being
used in investigations.55 It is postulated that the delivery of large num-
bers of cells may exacerbate the degenerative microenvironment due
to competing nutrient demands, which may in turn result in ineffective
clinical outcomes.56 Given the varying stages of degeneration and
microenvironments that exist in vivo, it will be important to tailor or
design treatments for individuals. One way to achieve this could be to
condition stem cells prior to implantation by acclimatizing them to
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patient specific in vivo microenvironmental milieu, which may include
inflammatory cytokines, acidity, oxygen or nutrient deprivation.57–59
These treatments must be assessed using appropriate in vitro and
ex vivo culture conditions which mimic those of the degenerate niche
to assess the likely behavior and survival of transplanted cells prior to
progressing to in vivo testing.49
4.2 | Primary cells, stem cells or gene therapy?
From a surgical and practical perspective, given the unique structure
and location of the disc, the difficulty in obtaining autologous primary
NP tissue and cells for therapeutic use from either herniated discs or
adjacent intact levels is clear. Delivery of primary NP cells to the disc
appears safe and has shown some potential for efficacy in early clini-
cal trials.60 Additional limitations of primary cells include the dimin-
ished tissue forming capacity of culture expanded NP cells derived
from degenerated tissue26 and the altered catabolic phenotype of
such cells, together with the paucity of NP cells that can be isolated.
Furthermore, the isolation of tissue from adjacent healthy disc levels
may increase the risk of initiating degeneration at the harvest site.61
This has motivated many researchers into identifying and characteriz-
ing alternative cell sources for disc regeneration, which is a key step
towards translating therapies into clinical practice.62 Primary, differen-
tiated cells from other skeletal sites with reduced risk for donor site
morbidity, such as articular and nasal cartilage, have been investigated
in vitro and in animal models for NP regeneration.63–65 While these
cell types do exhibit some phenotypic differences to native NP cells,
their relative ease of isolation, differentiated state and higher propen-
sity to deposit extracellular matrix may make them attractive alterna-
tives in the future and warrant further consideration and exploration.
The likelihood that these alternative cell types can adopt a true disco-
genic phenotype is remote, and whether the extracellular matrix con-
stituents they deposit are suitable to provide biomechanical
functionality and longevity to restore disc function remains to be fully
established.
Stem cell therapies have received considerable attention due to
their versatility, translatability and potential for long term native tissue
regeneration. Some successful patient outcomes have been demon-
strated in clinical studies using this approach.28,29,55,66–68 The bone
marrow has been the prime site of MSC isolation for disc regeneration
applications, inclusive of in vitro, preclinical and clinical studies.61,69
Progenitor cells derived from other tissue sources such as adipose tis-
sue have also been shown to possess significant potential for differen-
tiation and tissue forming capabilities.70,71 Adipose derived stem cells
(ADSCs) may provide a better alternative and candidate for cell ther-
apy and disc regeneration, due to their abundance and ease of isola-
tion, and may also have a lower inherent capacity than bone marrow
derived MSCs to undergo endochondral ossification.72 Harvesting of
autologous ADSCs can be performed in outpatient clinics with typical
yields of up to 25 000 adherent ADSCs per gram of tissue.73 One of
the potential challenges in utilizing stem cells is that they are undiffer-
entiated. The precise mechanism of action for regeneration is
unknown; whether injected stem cells have the capacity to differenti-
ate towards a discogenic phenotype or stimulate resident native cells
has not been clearly demonstrated in preclinical studies. Priming stem
cells using growth factors or other environmental cues such as altered
oxygen or glucose availability to direct or maintain a specific pheno-
type may enhance their regenerative potential,58,59,74–76 but may also
add complexity to the regulatory approval process.
Notochordal cell-based approaches for disc regeneration have
received considerable interest in the past several years. Notochordal
cells are the progenitors of adult NP cells, and their loss in humans
during postnatal growth is thought to contribute to the onset of
degeneration later in life.10 As notochordal cells themselves cannot be
readily obtained for direct clinical application, most studies have
focused on leveraging the therapeutic potential of notochordal cell-
secreted factors.77
Gene therapy approaches may hold significant promise for disc
regeneration, for example through silencing of catabolic or activating
anabolic pathways. Gene therapy has advantages over direct delivery
of proteins or small molecules, among them the possibility of sus-
tained efficacy through long-term, regulated, endogenous synthesis of
growth factors or anti-inflammatory factors.78 However, the need to
establish a safety profile and possible off target effects will most likely
lead to a longer and more complex regulatory process before realizing
a commercially available product and clinical translation.
4.3 | Effective cell delivery and retention
With respect to delivery of cell-based therapies, the primary mode of
choice has been injection through the AF. A key translational advan-
tage of this approach is that, with image-guided assistance, it can be
performed percutaneously. However, there are associated challenges
that have the potential to compromise both safety and efficacy,
including the potential for needles to induce permanent AF damage,79
cell leakage from the delivery site and diminished cell viability due to
shear forces as cells are forced through small diameter needles.80–82
For example, injecting a cell suspension into the lumbar discs of rab-
bits resulted in a 90% loss of the injected cells within the first
30 minutes.83 Biomaterials as delivery vehicles, and in particular
hydrogels, have been utilized to overcome retention issues and pro-
vide additional support for cell survival and phenotype retention.84–89
Injectable biomaterial systems utilizing alginates, collagens, hyaluronic
acid, fibrin and a variety of other substances have all shown promise
for improving cell delivery for disc repair90–92; however, for clinical
translation, the biomaterial itself will require regulatory approval.
Using biomaterials already approved and in clinical use for other indi-
cations may accelerate the approval process. That being said, because
the disc is avascular, carrier degradation products may accumulate to
levels beyond those found in other target tissues, justifying disc-
specific toxicity testing. Selection of needle size for trans-annular
delivery should be a careful trade-off between the minimum size nec-
essary to prevent shear-induced cell death and allow injection of vis-
cous hydrogels, and the maximum size necessary to prevent
permanent AF damage and/or cell leakage. In a recent study using a
preclinical large frame goat model, a 22G needle was found not to
induce discernable degenerative changes on MRI or histology after
12 weeks.93 In addition, the volume to be delivered needs to be opti-
mized, as excessive volumes may result in over pressurization, increas-
ing the likelihood of cell leakage upon needle withdrawal. Further, the
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spatial distribution of delivered cell populations may also impact cell
differentiation or activity and subsequent regeneration outcomes, as
injected materials will tend to preferentially concentrate within pre-
existing fissures that are common in degenerated discs. For hydrogel-
delivered cell populations, migration of cells through the NP and inte-
gration of the injected material with native tissue should be consid-
ered. An alternative delivery route that has been investigated, and
which does not cause disruption to the AF, is through the pedicles/
endplates (transpedicular approach);94,95 however, whether such an
approach will have detrimental effects to the integrity of the endplate
in the long term is yet to be established.
5 | MINIMIZING POTENTIAL RISKS TO
PATIENTS
Demonstrating safety is critical for disc therapies, as the conse-
quences of an adverse event are potentially severe. The disc is one of
the most highly loaded tissues in the body, which creates the signifi-
cant potential that injected biomaterials will migrate in response to
long term, cyclic loading. Material that is expelled from the disc space
may impinge on nerves and result in neurological complications or
even paralysis. Therefore, a fundamental safety requirement of a disc
therapy, particularly one that involves a structural component such as
a hydrogel or scaffold, is that it structurally integrates, and remains
completely and permanently contained within the disc space upon
delivery. Retention should be verified in the presence of physiological
loading; ex vivo, this can be accomplished through extensive cyclic
and multiaxial loading. Long term in vivo retention can be assessed via
incorporation of radiopaque contrast agents or nanoparticles at the
time of delivery, facilitating non-invasive and three dimensional longi-
tudinal assessments.85
Ensuring that a therapy does not impart local or systemic toxicity
is also a critical safety consideration, and in vivo biocompatibility stud-
ies are generally a requirement of the FDA (food and drug administra-
tion) and other regulatory bodies for new biological therapies. Toxicity
could potentially result directly from the implanted material, or over
time from its degradation by-products. For example, biomaterials that
break down into acidic by-products in the confined space of the disc
could contribute to eliciting a catabolic, local, cellular response.96 Tox-
icity and biocompatibility can be assessed in vitro through cellular co-
culture studies and tissue or organ culture studies, and in vivo via
implantation subcutaneously as well as in the disc space itself. Out-
come measures from in vivo studies may include assessing the viabil-
ity of endogenous cells and recruitment of neutrophils, macrophages,
mast cells and fibroblasts, and the extent of fibrous encapsulation at
the site of implantation, which can provide indications of an inflamma-
tory response. Monitoring for signs of systemic toxicity (acute and
chronic) is also essential, through assessment of changes in behavior,
weight and appetite, reflexes and sensitization, in addition to blood
chemistry, hematology and anatomic pathology.
Prior to clinical testing, stem cell therapies must be carefully vet-
ted in vitro and through preclinical studies. Genetic instability of
undifferentiated, multi- or pluripotent cells poses a safety risk as it
increases the chances of tumorigenesis and cancer.97 Pluripotent stem
cells such as embryonic and induced pluripotent stem cells exhibit
intrinsic genetic instability that can result in teratoma formation.97
Emerging non-integrating techniques for cellular reprogramming, for
example using synthetic mRNA or chemical methods, may mitigate
these risks without compromising induction efficiency.98,99 Adult,
multipotent stem cells, while not exhibiting the same tumorigenic risk
as pluripotent stem cells, may also exhibit genetic instability through
chromosomal aberrations that manifest progressively with increasing
numbers of expansion passages.97 Minimizing the length of culture
and degree of cellular manipulation prior to implantation minimizes
the propensity for these in vitro genetic alterations to occur. Asses-
sing the heterogeneity of stem cell populations in culture is also
important to reduce tumorigenic and immunogenic risk.
Gene therapy, which employs cellular reprogramming, poses
unique safety challenges that may limit or complicate translatabil-
ity.100 These risks, which include the potential for insertional muta-
genesis and cancer, and antigenicity with associated adverse
immunological responses, result in additional regulatory hurdles,
which may be harder to overcome for therapies targeting non-life-
threatening conditions such as disc degeneration. Risks associated
with gene therapy may be mitigated through careful selection of gene
delivery systems (eg, viral vs non-viral), which minimize risk without
comprising efficacy.101
The method and frequency of administration will also impact a
therapy's safety profile. Therapies that can be delivered using mini-
mally invasive procedures, such as image-guided percutaneous injec-
tion, and do not require general anesthesia, will pose less risk to
patients than therapies that require an open surgical approach. Exam-
ples of such therapies might include injection of stem cells, hydrogels
or drugs directed at the NP. Other strategies, such as implantation of
cell-seeded engineered constructs to repair or replace degenerate disc
tissue, may necessitate an open surgical approach, however the
required surgical procedures should carry no greater risk than those in
current clinical use. Similarly, therapies that require a single adminis-
tration to achieve long term efficacy will have a more attractive safety
profile than those that require multiple administrations.
6 | SELECTING PHYSIOLOGICALLY AND
CLINICALLY RELEVANT EFFICACY METRICS
6.1 | Defining and understanding the clinical
problem
Optimization of disease-modifying activity should be informed by
knowledge of the patient, their clinical needs, and underlying pain and
disability mechanisms. The most important objective of a treatment
for painful disc degeneration is long term (>6 months) alleviation of
symptoms. Current treatment strategies, whether they be conserva-
tive or surgical, may be effective in providing short term relief from
pain, but their long-term efficacy is more problematic, in part because
they do not seek to restore disc structure or mechanical function.
Given the nature of disc degeneration and its cascading effect on
adjacent tissues and overall spine mechanical properties, it is often
difficult to specify the fundamental treatment target. Disruption of
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normal disc biomechanical properties is associated with accelerated
degeneration of other structures such as facet joints, and osteophyte
formation due to adaptive bony changes or calcification of liga-
ments.102,103 Back pain patients commonly have associated leg pain
and symptoms which are frequently secondary to nerve compression,
due to stenosis caused by loss of disc height and/or bulging or hernia-
tion. Consequently, stabilization (if not restoration) of disc structure is
a key goal.
Back pain can also arise from irritation of peripheral disc tissues.
For example, pro-inflammatory crosstalk between the disc and verte-
bra is thought to underlie bone marrow edema evidenced as Modic
changes (MC) on clinical MRI.104 Cellular expression of cytokines (eg,
IL-1, −6, and −10, and RANKL)104,105 with MC is linked to endplate
erosions which strongly associate with back pain.106,107 These obser-
vations indicate that inflammation suppression is another important
therapeutic goal.
For cell therapies to be clinically adopted, they need to demon-
strate benefits beyond current treatment options. The rationale for
choosing between surgical and nonsurgical care for chronic low back
pain patients is not well-defined. While the benefit of surgery for
“mechanical” back pain (such as instability and sciatica) is supported
by significant outcome literature, the appropriate intervention for
disc-related pain is less clear. Fusion surgery may alleviate pain by
restoring intervertebral height and decompressing nerves, but immo-
bilizes the intervertebral joint.15,17 Metal/polymer-based total disc
arthroplasties preserve a limited degree of joint mobility, but are sub-
ject to wear and potential failure requiring revision surgery, and have
not seen widespread adoption.108 Reported success of surgical care
for back pain ranges from 41% to 57%,109 and with 5% to 16% early
complication and reoperation rates.110 Discectomy may alleviate
symptoms by removing herniated or bulging disc material and decom-
pressing nerves, but the damaged disc is not repaired and may con-
tinue to degenerate, and many patients continue to experience pain
and require ongoing treatment.111 Non-surgical approaches such as
steroid injections and physical therapy are temporary treatments that
seek to mask symptoms that might otherwise resolve over time.
Recurrent treatment for unresolving symptoms is more problematic as
permanent nerve damage can occur. Non-surgical, like surgical, treat-
ment does not alter the long term progression of degeneration. Resto-
ration of disc biomechanical function is therefore key to effective
long-term alleviation of painful symptoms.
The primary attraction of biological, cell-based disc regeneration
therapies is that they have the potential to alleviate symptoms and
stabilize disc structure as well as biomechanical function by reconsti-
tuting native tissue structures. When delivered in combination with a
structural biomaterial such as a hydrogel or composite scaffold, cell-
based therapies can provide immediate normalization of disc structure
and mechanical function, while bioactive elements such as cells or
growth factors work in vivo to suppress inflammation and progres-
sively replace the biomaterial with native tissue. The three most
important objectives to demonstrate efficacy of biological disc regen-
eration therapies are therefore alleviation of pain, stabilization or res-
toration of structure, and normalization of biomechanical function.
Outcome measures for in vitro, in vivo preclinical, and clinical evalua-
tion of such therapies should be selected with these goals in mind.
6.2 | Appropriate selection and implementation of
model systems to demonstrate efficacy
Pre-clinical demonstration of efficacy and safety using in vitro and
in vivo model systems is an iterative process (Figure 1), and typically
begins with simple two-dimensional (2D) or three-dimensional
(3D) cell culture models that have limited biological complexity but are
cost effective and high throughput. Experiments may then progress to
more complex 3D culture models or organ culture systems that incor-
porate more elements of the in vivo cellular environment. Smaller ani-
mal models such as mice, rats or rabbits may then be used to establish
preliminary in vivo efficacy, and immunocompromised small animal
models enable preliminary in vivo evaluation of human cells. Preclini-
cal evaluations may then be conducted using larger animals such as
pigs, sheep, goats or dogs. The reason for such an iterative approach
to demonstrating therapeutic efficacy reflects the need to balance
experimental control, cost and throughput on the one hand during
proof-of-concept, with the need to incorporate biological complexity
and demonstrate long term efficacy on the other, to progress towards
clinical translation. At a minimum, a broad understanding of the bio-
logical mechanisms underlying cell-based regeneration strategies is
required to achieve efficacy, both for hypothesis generation at the
study outset and to direct troubleshooting and optimization.
In order to maximize the physiological relevance of experimental
data, it is important that model systems effectively recapitulate the
in vivo cellular microenvironment of the degenerate human disc. If
therapeutic efficacy is evaluated only under idealized experimental
conditions, the chances of failure upon preclinical or clinical transla-
tion are high. While this is true to an extent for therapies targeting
any number of conditions (ie, not just disc degeneration), the disc
microenvironment poses unique challenges—biochemical, biophysical
and biomechanical—to therapeutic cell survival and function. With
respect to the biochemical environment, as the disc has little or no
direct blood supply, the cells must survive and function with access to
very limited oxygen and nutrition. As discs degenerate, even in the
early stages, this biochemical environment is further characterized by
increasing local catabolic cytokine expression112 and acidity.113 Thera-
peutic cell types such as MSCs are more sensitive to microenviron-
mental stressors such as oxygen, nutrient deprivation and
inflammatory stimuli compared to endogenous cells.114–116
For in vitro cell culture models, mimicking this in vivo disc
microenvironment can be accomplished by culturing cells in low
oxygen, and reduced glucose and serum, to simulate nutrient
deprivation.115–117 The degenerate environment can be further sim-
ulated by including catabolic mediators such as inflammatory cyto-
kines and by increasing acidity.118–120 The physical environment can
be mimicked through culturing in soft 3D scaffolds such as hydro-
gels. Mechanical stress can be simulated using bioreactors that apply
dynamic compressive loads and/or hydrostatic pressure.121–124
Organ culture systems that employ living, degenerate discs from
human donors may be the ultimate platform to effectively mimic
the biological complexity of the in vivo cellular microenvironment,
particularly when combined with a bioreactor that applies physiolog-
ical loading.125
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Ensuring accurate recapitulation of the human disc cellular micro-
environment is equally important when moving to in vivo systems.
One of the greatest challenges facing in vivo models of disc therapeu-
tics is the need to replicate the size, and in particular the height of the
human disc, necessary to accurately recapitulate physiological nutri-
tional demands. Large animals obviously more closely approximate the
nutritional environment compared to rodents, however, even in live-
stock, lumbar disc size is still significantly smaller than in humans (eg,
lumbar disc height in sheep is ~4 mm compared to ~11 mm in
humans).126
Therapeutic cell types such as MSCs may exhibit different pheno-
typic characteristics as a function of donor, age, species and anatomi-
cal site, and these characteristics may be closely linked to
regenerative potential.127–130 While the development phase may
necessitate the use of non-human cells that are accessible and com-
patible with in vitro and in vivo models, the results obtained with
FIGURE 1 Requisite steps for demonstrating the efficacy of cell-based disc regeneration therapies. Model systems should be applied iteratively,
balancing experimental control, cost and throughput in the early stages with biological complexity and clinical relevance at more advanced stages,
in order to maximize the chances of success in the clinic
SMITH ET AL. 7 of 14
these cells may not accurately reflect the performance of human cells
that will be used clinically. It is therefore important to validate findings
using cells from human donors, wherever possible controlling for vari-
ables such as age, sex, co-morbidities and anatomical site. Human cells
may be obtained both from commercial sources, as well as from clini-
cal collaborators undertaking spinal procedures. The latter of these
sources is particularly attractive where it permits recruitment of
donors who would also be prospective recipients of disc therapeutics.
For example, a surgeon performing a procedure such as a spinal fusion
may be able to provide not only surgical waste tissue as a source of
endogenous disc cells, but also bone marrow from the adjacent verte-
brae without subjecting the patient to any additional surgical proce-
dures or risks. As already discussed, organ culture using degenerate
human discs obtained from cadavers represents an avenue for evalu-
ating therapeutic efficacy not only using human cells, but also in a
physiologically accurate and degenerative microenvironment. The
importance of cell source also extends to the preclinical development
phase. For example, a therapy that demonstrates efficacy in vitro
using cells of a particular age and species, may not demonstrate similar
efficacy in a large animal model of a different age and species. In vitro
studies should therefore seek to validate a therapeutic approach using
cells from the full range of sources that will be required at each phase
of development.
6.3 | Pain and disability outcome measures
As alleviation of pain is the primary goal of disc therapies, including
pain as an outcome measure in laboratory experiments is desirable.
Selection of physiologically-relevant pain outcome measures in the
preclinical setting is complicated, as in the clinical setting pain is sub-
jective and its direct source may be ill-defined.131,132 Pain outcome
measures can be classified in different ways. They may include surro-
gates such as nerve ingrowth and regression,133,134 local and systemic
levels of secreted neurogenic and inflammatory factors,135,136 as well
as imaging to demonstrate nerve compression.45 Direct outcome mea-
sures of pain may include assessments of overall behavior and mobil-
ity, and pain sensitivity assays.137 Small animal models are particularly
attractive with respect to assessing pain, as they are compatible with
most if not all of these outcome measure types. For example, if a ther-
apy is being evaluated in a mouse or rat, it is possible and practical to
assess mobility, pain sensitivity, and serum and radiological biomarkers
in vivo, and tissue level expression of neurogenic markers post mor-
tem. Using in vitro models, pain outcomes are limited to surrogates
such as expression of neurogenic factors and nerve ingrowth. Large
animal models are in theory compatible with many of the same out-
come measures as small animal models, but practical considerations
make implementation of functional and pain sensitivity assays more
challenging.
6.4 | Structural and biomechanical outcome
measures
Including appropriate outcome measures to assess restoration of disc
structure and mechanical function is equally important, as these are
the key indicators of the likelihood for a therapy to provide long term
alleviation of symptoms. Like pain, the ability to assess these parame-
ters directly or indirectly is dependent on the type of model system.
With respect to structure, the most clinically relevant outcome mea-
sure is stabilization or restoration of disc height as demonstrated
through imaging (MRI, plain radiographs or computed tomography),
and is possible for in vivo models as well as in vitro whole-disc organ
culture models.93,138,139 Importantly, these non-invasive imaging met-
rics can be applied longitudinally and thus used to confirm both acute
regenerative effects and sustained, long term efficacy. With respect
to biomechanical properties, in vitro model systems that incorporate
three-dimensional constructs or whole-disc organ culture facilitate
direct assessment of mechanical function.89,140 For in vivo models,
mechanical properties can be assessed ex vivo on intact spinal motion
segments or isolated tissue samples.85 In the case of motion seg-
ments, multi-axis loads can be applied to similar physiological defor-
mations, including those likely to lead to failure.141 Direct, in vivo
evaluation of disc mechanical properties is possible using emerging
technologies such as magnetic resonance elastography.142,143 Where
direct evaluation is impossible, assessments of extracellular matrix
composition and organization through biochemical and histological
assays, or imaging (eg, MRI or contrast-enhanced CT), represent
important surrogates for mechanical function.33–37
7 | MAXIMIZING COMMERCIAL POTENTIAL
Given the vast socio-economic costs associated with low back pain
and the high costs of current treatment approaches, it would appear,
superficially, to be straight forward to establish the commercial case
for a new disc therapy, particularly one for which clinical safety and
efficacy can be established. However, bringing a biological disc ther-
apy to market is a long, complex and expensive process, and one that
to date has been met with little success. Basic scientists, including
those working in the translational space, are often focused foremost
on probing basic mechanistic questions and rapidly disseminating find-
ings. They may be less concerned about addressing questions of com-
mercial viability, despite this being an essential criterion for
widespread clinical adoption. A new biological therapy may “check”
key boxes with respect to safety and efficacy in vitro, in animal
models, and even in clinical trials, but fail at the final hurdle if it is not
perceived as commercially viable. Some of the factors impacting
potential commercial viability can be addressed early on, including
clearly identifying the prospective target patient population size, pro-
tecting intellectual property, and assessing the competitive landscape.
Other factors should be considered and continuously reviewed as the
concept evolves, including complexity, cost of components and prepa-
ration time, in addition to the ease and method of administration.
Early and frequent discussions with regulators (eg, FDA) are key to
defining the studies required to translate such products into the clinic,
and to ensure that manufacturing approaches will meet the standards
required for human testing.
One predictor of the potential commercial viability of a new ther-
apy is the size of the prospective target patient population. Further,
the overall manufacturing costs associated with producing the
product, in contrast to the reimbursement/pricing potential of the
8 of 14 SMITH ET AL.
treatment, must be favorable. In considering the clinical motivation for
developing a specific biological disc therapy, the overall socioeco-
nomic burden is often cited, as is the current lack of effective treat-
ment options. In establishing and justifying the clinical need for a
specific, new therapeutic approach, it is necessary to move beyond
general patient populations (ie, “degenerative disc disease”) and
stratify subgroups of patients that will be suitable candidates for that
therapeutic approach based on the specific disease features experi-
enced. For example, injectable disc therapies may be tailored to target
a patient subgroup that exhibits a specific set of symptoms or a
narrow window of degeneration severity that includes an intact annu-
lus and relatively healthy endplates. The need for a therapy targeting
symptomatic low back pain in patients with mild to moderate severity
disc degeneration (eg, minimally invasive cell therapy) could be justi-
fied by citing the number of patients in this subgroup that are not can-
didates for surgery and are unresponsive to conservative treatment
approaches. Alternatively, the need for a new therapy targeting
patients with severe disc degeneration (eg, tissue engineered total
disc replacements) could be justified by citing the number of patients
that exhibit poor outcomes from current surgical approaches such as
fusion or total disc arthroplasty.
The second important consideration to ensure future commercial
viability is early protection of relevant intellectual property. At most
academic institutions, protection of intellectual property begins by
submitting an invention disclosure to the relevant university office,
which will then assess the concept or technology for commercializa-
tion potential. Such disclosures are a requirement for any potentially
patentable invention, and institutions may stipulate that this should
be done in advance of any public disclosure (eg, publication of manu-
scripts or conference presentations). Without such protection before
public disclosure, the ownership is lost, and no patent may be filed,
significantly decreasing the chances of the product ever being trans-
lated to the clinic. Following disclosure, where an invention is identi-
fied as having commercialization potential, the institution should be
equipped to guide the investigator through the intellectual property
protection process, including filing of patents. Trade secrets represent
an alternative approach to patenting an idea, though not one neces-
sarily supported by academic institutions. When a patent is published
and becomes public, smart competitors have the opportunity to cir-
cumvent it by implementing minor alterations or improvements to the
overall concept. In the case of trade secrets, key properties of the
product that are critical to its function never enter the public domain.
The relative cost and complexity of a therapeutic strategy, with
respect to production, preparation and administration will also impact
commercial viability. A complex and costly in vitro approach may be
necessary during early stages of development; however, investigators
should consider how this can be reduced as the development process
advances towards preclinical and clinical translation. This process of
refinement might include minimizing (or eliminating) the number of
growth factors, cell types or biomaterial components, substituting
growth factors with cheaper compounds, and reducing the time
needed for in vitro manipulation prior to administration, which may
include cell expansion or conditioning.
For first or second generation therapeutic products, investigators
should also be cognizant and take steps at an early stage to avoid
developing “complex” approaches, which will most likely face signifi-
cant regulatory hurdles and barriers. For example, this might include
considering using autologous vs allogeneic cells, or using appropriately
conditioned and sourced adult stem cells vs pluripotent cells that
require viral reprogramming. Therapies that require in vitro manipula-
tion using animal serum face tough regulatory hurdles and alternative
culture conditions should be considered. If the approach includes gene
therapy, then gene delivery systems with the best safety profile
should be selected. The number of regulatory hurdles could be further
reduced by incorporating or substituting compounds that have an
established safety record and are already FDA approved for other
indications.
The final important consideration with respect to ensuring com-
mercial viability is to undertake a comprehensive survey of the current
competitive landscape. This requires identifying competing therapeu-
tics, including those in clinical use and those undergoing clinical or
preclinical trials, that target a similar cohort of patients, and reviewing
where those competing products are with respect to the development
pipeline. If a competing product has not already come to market, it
should be estimated when that is likely to happen. Even if the number
of competing products is relatively small, factors such as relative risk,
cost and potential efficacy compared to the therapy being proposed
should be assessed.
8 | THE IMPORTANCE OF
MULTIDISCIPLINARY COLLABORATION
AND ENGAGING WITH CLINICIANS
Closely linked to commercial viability and prospective market uptake
is the willingness of clinicians to embrace the newly developed thera-
peutic approach. There may be resistance within a particular market
sector to switch away from traditional treatment approaches, for
example, for philosophical, financial or logistical reasons. To ensure a
new disc therapy will successfully and effectively translate from the
lab to the clinic, basic scientists must therefore work to ensure that
the new product will ultimately be enthusiastically embraced by those
clinicians required to administer it. To achieve this, it is essential to
engage clinicians early and continuously from inception through to
translation, and these clinical collaborators may well already be pas-
sionate about identifying novel treatment strategies for their low back
pain patients. Not only will the participation of clinicians (as the end
users) aid market acceptance, it will also add significant value to the
overall scientific endeavor. In the early stages, clinicians will be able to
draw on their extensive, firsthand experience to help identify prospec-
tive target patient populations, and advise on existing treatment
modalities and their limitations. As development progresses through
in vitro evaluations, clinical collaborators can provide access to primary
human cells, for example from surgical waste tissue, that can be used
to maximize the physiological relevance of results. During preclinical
evaluation in animal models, clinical collaborators can work to opti-
mize application of the treatment, surgically or otherwise, advise on
selection of clinically relevant outcome measures and evaluate success
benchmarks. As a therapy approaches clinical translation, clinical col-
laborators can disseminate and promote preclinical findings to
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colleagues at clinical scientific meetings, assist with the design and
conduct of clinical trials, including recruitment of trial participants,
navigate the regulatory landscape, and advocate the treatment to
patients and health systems. It is thus crucial that clinical collaborators
fully understand the character of the product and underlying science.
Engagement with clinicians can also be enhanced through dissemi-
nation of research findings not only at major basic science-intensive
meetings such as the Orthopedic Research Society (ORS), but also at
meetings that have stronger clinical participation, such as those of the
International Society for the Study of the Lumbar Spine (ISSLS), the Cer-
vical Spine Research Society (CSRS), the North American Spine Society
(NASS), the American Academies of Orthopedic (AAOS) and Neurological
(AANS) surgeons. Clinicians are frequent and active participants in these
meetings, and constitute leadership positions, and are thus the ideal
advocacy vehicles in these fora. Equally, it is pivotal to promote and
encourage multidisciplinary interactions at both scientific and clinically
focused meetings to accelerate the field towards clinical translation and
ensure we maximize our efforts in treating degenerative disc disease.
9 | SUMMARY
Despite an overwhelming clinical need, cell-based therapies for disc
degeneration and low back pain have to date failed to achieve wide-
spread clinical adoption. Over the last decade, tremendous advances
have been made towards understanding the underlying pathophysiol-
ogy, defining and optimizing therapeutic cell types, and refining and
applying physiologically relevant model systems for their evaluation.
The goal now must be to more effectively translate laboratory findings
into the clinic to achieve improved patient outcomes. To this end, the
primary intention of this perspective from members of the Orthopedic
Research Society Spine Section is to provide a consensus with respect
to the central challenges that have limited effective clinical translation
of cell-based therapies. Motivating this perspective was a uniform and
sincere belief among Spine Section members that cell-based therapies,
if effectively designed and implemented in conjunction with appropri-
ate diagnostic tools, patient selection criteria, and with the support of
industry partners have the potential for substantial clinical impact.
Recommendations for researchers to effectively address these chal-
lenges are provided, falling broadly under the key themes of “Safety,
Efficacy, Commercial Viability and Engaging Clinicians” (summarized in
Table 1). The authors urge researchers to consider and leverage these
recommendations to enhance the translational relevance and clinical
potential of their research endeavors and activities.
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TABLE 1 Key recommendations for successful clinical translation of injectable cell-based disc therapies
Safety Efficacy Commercial viability Engaging clinicians
• Demonstrate long term
retention in the disc space under
physiological loading
• Select experimental outcomes
relevant to the overall goal of
long term alleviation of symptoms
through stabilization/ restoration
of disc structure and
biomechanical function
• Identify the size of the
prospective target patient
population
• Engage clinicians early and
continuously during development
• Evaluate acute and chronic, local
and systemic toxicity in vitro
and in vivo, and include effects
of degradation products
• Apply model systems iteratively,
balancing experimental control,
cost and throughput in the early
stages with biological complexity
and clinical relevance at more
advanced stages
• Protect intellectual property early
by submitting an invention
disclosure to the relevant
university office
• Anticipate resistance to switching
away from current therapeutic
approaches
• Minimally invasive delivery
carries less risk than an open
surgical approach
• Design model systems to
appropriately mimic aspects of
the in vivo chemical, physical and
mechanical microenvironments of
the disc
• Minimize cost and complexity
with respect to production,
preparation and administration
• Clinicians can provide primary
human sourced material for
in vitro testing, and develop and
refine techniques for in vivo
modeling and therapeutic
administration
• Aim for a single administration
vs multiple administrations
• Consider the confounding effects
of species, age and sex on
efficacy in vitro and in animal
models
• Minimize the number of potential
regulatory hurdles
• Clinicians can advise and lead
design and implementation of
clinical trials, including patient
recruitment
• Maximize genetic stability of
stem cell therapies by
minimizing in vitro manipulation
• Incorporate human-sourced cells
and tissues into experiments
• Undertake a comprehensive
survey of the competitive
landscape
• Clinicians can advocate new
therapeutic approaches to
patients and health systems,
accelerating their early and
widespread adoption
• Autologous cell therapies pose
less of a risk than allogeneic
• Where outcomes such as pain or
mechanical properties cannot be
measured directly, carefully
justified, clinically relevant
surrogates should be used
• Clinicians can facilitate
dissemination and promotion of
new therapeutic approaches to
colleagues at clinical scientific
meetings
• Clearly define success
benchmarks for all experimental
outcomes
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